See more : American Aires Inc. (AAIRF) Income Statement Analysis – Financial Results
Complete financial analysis of Molecular Partners AG (MOLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Molecular Partners AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Talon Energy Ltd. (TPD.AX) Income Statement Analysis – Financial Results
- PDG Realty S.A. Empreendimentos e Participações (PDGR3.SA) Income Statement Analysis – Financial Results
- Deep Blue Marine, Inc. (DPBE) Income Statement Analysis – Financial Results
- Gish International Co., Ltd (8067.TWO) Income Statement Analysis – Financial Results
- Zhejiang Longsheng Group Co.,Ltd (600352.SS) Income Statement Analysis – Financial Results
Molecular Partners AG (MOLN)
About Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.04M | 189.56M | 9.33M | 9.34M | 20.38M | 10.36M | 20.02M | 23.04M | 29.12M | 26.63M | 32.42M |
| Cost of Revenue | 47.84M | 50.75M | 55.72M | 56.08M | 43.50M | 15.60M | 17.82M | 14.57M | 1.17M | 170.75K | 1.22M |
| Gross Profit | -40.81M | 138.81M | -46.39M | -46.73M | -23.12M | -5.25M | 2.19M | 8.47M | 27.95M | 26.45M | 31.20M |
| Gross Profit Ratio | -579.80% | 73.23% | -497.19% | -500.12% | -113.40% | -50.67% | 10.96% | 36.76% | 96.00% | 99.36% | 96.23% |
| Research & Development | 48.78M | 50.75M | 55.72M | 56.08M | 43.50M | 38.20M | 37.45M | 35.19M | 23.92M | 18.79M | 20.82M |
| General & Administrative | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 57.00K | 5.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.54K |
| SG&A | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Other Expenses | -47.48M | 372.00K | 125.00K | 568.00K | 381.00K | -9.76M | -12.12M | -9.38M | 4.16M | 4.29M | 2.29M |
| Operating Expenses | 20.30M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Cost & Expenses | 68.15M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Interest Income | 4.28M | 1.14M | 99.00K | 367.00K | 1.60M | 693.00K | 610.00K | 335.00K | 357.52K | 347.85K | 234.82K |
| Interest Expense | 49.00K | 605.00K | 548.00K | 271.00K | 27.00K | 591.00K | 197.00K | 89.00K | 216.00 | 853.00 | 226.53K |
| Depreciation & Amortization | 2.42M | 2.39M | 2.57M | 2.89M | 2.47M | 924.00K | 1.15M | 1.09M | 909.39K | 809.53K | 793.02K |
| EBITDA | -59.53M | 120.85M | -60.85M | -59.59M | -33.71M | -36.27M | -24.70M | -18.06M | -1.02M | -1.47M | 7.93M |
| EBITDA Ratio | -845.84% | 63.37% | -651.25% | -589.73% | -160.26% | -350.25% | -120.35% | -78.39% | -3.51% | 11.23% | 25.10% |
| Operating Income | -61.11M | 116.61M | -63.42M | -58.33M | -36.66M | -37.41M | -25.84M | -19.49M | -2.22M | 1.84M | 7.12M |
| Operating Income Ratio | -868.26% | 61.52% | -679.72% | -624.21% | -179.86% | -361.27% | -129.12% | -84.57% | -7.62% | 6.91% | 21.95% |
| Total Other Income/Expenses | -876.00K | 1.24M | -365.00K | -4.45M | 389.00K | 374.00K | 414.00K | 874.00K | 2.07M | -4.12M | 24.93K |
| Income Before Tax | -61.98M | 117.85M | -63.78M | -62.78M | -36.27M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Income Before Tax Ratio | -880.70% | 62.17% | -683.63% | -671.82% | -177.95% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| Income Tax Expense | 0.00 | -1.24M | 2.00K | -11.00K | 17.00K | -591.00K | -414.00K | -874.00K | -2.07M | 4.12M | -226.53K |
| Net Income | -61.98M | 117.85M | -63.79M | -62.76M | -36.29M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Net Income Ratio | -880.70% | 62.17% | -683.65% | -671.70% | -178.03% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| EPS | -1.89 | 3.63 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| EPS Diluted | -1.89 | 3.54 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| Weighted Avg Shares Out | 32.77M | 32.47M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.22M | 19.49M |
| Weighted Avg Shares Out (Dil) | 32.77M | 33.27M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.29M | 19.49M |
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
Molecular Partners: A Speculative Bet On Innovative DARPin Technology
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
Source: https://incomestatements.info
Category: Stock Reports